PDCD1 and non-small cell lung carcinoma: In particular, in the case of pembrolizumab, which has received FDA approval as first line therapy for metastatic NSCLC, accurate evaluation of PD-L1 expression in advanced stage patients, which can only be performed with biopsy, is crucial for identifying patients to be a candidate to anti-PD-1 therapy [5, 22].